Ascot buys German chemical group for pounds 90m
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
SHARES IN Ascot, the industrial group, surged by 6 per cent yesterday following the announcement of the acquisition of the Haltermann Group, a German chemical group, for pounds 90m.
In a statement, Ascot said that the purchase "creates a world-leading business in the chemicals outsourcing market, which has attractive growth potential".
The company will fund the DM250m purchase through the issue of pounds 31m of shares, while the remainder will be paid in cash. The Haltermann board will retain more than half of the newly issued shares.
The acquisition of Haltermann, which last year reported a pre-tax profit of pounds 9.4m on a turnover of pounds 130m, will make Ascot the world's largest contract chemical processor, with 50 per cent market share in Europe, and 30 per cent in the US.
Contract chemical processing, the manufacture of small batches of specialist chemicals outsourced by bigger companies, is perceived by the City as a stable business.
"It is an excellent part of the industry to be in. You don't have anything like the cycles of the commodity chemical business, or even speciality chemicals," said one analyst.
Dresdner Kleinwort Benson, the house broker, upped its full-year pre- tax profit forecasts by 7 per cent. With a share price of 250p, many believe that the forward p/e ratio of 7.5 is too low.
Ascot is also expected to benefit from a joint venture with ChiroTech, which makes a chemical compound for Glaxo's new anti-Aids drug, Abacavir, due to be launched in January.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments